πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors β€” phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β€” searchable for business development and competitive intelligence.

Showing page 129 of 857 Β· Phase 3 first, then by program name

  1. PL2200 Aspirin Capsules

    Protalix BioTherapeutics

    Diabetes Mellitus, Type 2

    phase 3 small molecule completed

    2 trials

  2. PLACEBO DE COLCHICINE 1 mg, COLCHICINE OPOCALCIUM 1 mg, comprimΓ© sΓ©cable

    Pari Pharma GmbH

    patients suffering from acute myocarditis confirmed on Cardiac magnetic resonance imaging.

    phase 3 small molecule active

    1 trial

  3. PLACEBO FOR PF-06651600-15 CAPSULE, 100 MG, Ritlecitinib Tosilate, PLACEBO FOR PF-06651600-15 CAPSULE, 50 MG, Ritlecitinib tosilate

    Pfizer Australia Pty Ltd

    Alopecia areata

    phase 3 small molecule active

    1 trial

  4. PLACEBO OF BELIMUMAB, Benlysta 200 mg solution for injection in pre-filled pen.

    Pari Pharma GmbH

    Adult patients with persistent or chronic immune thrombocytopenia

    phase 3 small molecule active

    1 trial

  5. PLACEBO OF VANCOMYCINE = NaCl 0.9% ( oral use ), Vancomycine Viatris 500 mg poudre pour solution pour perfusion

    Pari Pharma GmbH

    Patients hospitalized for allogeneic hematopoietic stem cell transplantation

    phase 3 small molecule active

    1 trial

  6. PLACEBO SOTAGLIFLOZIN, SOTAGLIFLOZIN

    LEXICON PHARMACEUTICALS, INC.

    Obstructive Cardiomyopathy, Hypertrophic, Non-obstructive Hypertrophic Cardiomyopathy

    phase 3 small molecule active

    1 trial

  7. PLACEBO for GIVINOSTAT hydrochloride monohydrate (ITF2357) 10 mg/mL oral suspension, ITF2357

    Italfarmaco S.p.A.

    Duchenne muscular dystrophy (DMD)

    phase 3 small molecule active

    1 trial

  8. PLACEBO, IMFINZI 50 mg/mL concentrate for solution for infusion., MYCOPHENOLATE MOFETIL, INFLIXIMAB, DOMVANALIMAB

    AstraZeneca AB

    The target population of interest in this study is participants with locally advanced (Stage III), unresectable NSCLC, whose tumours express PD L1 TC β‰₯ 1% as assessed by a central reference laboratory using the VENTANA PD-L1 (SP263) IHC assay, and who did not progress after definitive platinum based cCRT.

    phase 3 small molecule active

    1 trial

  9. PLACEBO, Nicetile 500 mg polvere per soluzione orale

    Istituto Gentili S.r.l.

    amyotrophic lateral sclerosis

    phase 3 small molecule active

    1 trial

  10. PLASMA, Omniplasma 45-70 mg/ml oplossing voor infusie

    Disc Medicine

    Coagulation in pediatric cardiac surgery

    phase 3 small molecule active

    1 trial

  11. PLENVU Pulver zur Herstellung einer Losung zum Einnehmen, SODIUM PICOSULFATE

    Norgine Pty.

    Colonic disease

    phase 3 small molecule active

    1 trial

  12. PLERIXAFOR, Casgevy 4 - 13 x 10^6 cells/mL dispersion for infusion, BUSULFAN, FILGRASTIM

    Vertex Pharmaceuticals (Australia) Pty.

    Transfusion-dependent Ξ²-thalassemia (TDT), Severe sickle cell disease (SCD)

    phase 3 small molecule active

    1 trial

  13. PLX-200

    Polaryx Therapeutics

    Juvenile Neuronal Ceroid Lipofuscinosis

    phase 3 small molecule active

    1 trial

  14. PONATINIB, PONATINIB, Ponatinib, IMATINIB, IMATINIB

    Takeda

    Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

    phase 3 small molecule active

    1 trial

  15. PRAX-114

    Chongqing Precision Biotech Co., Ltd

    Major Depressive Disorder

    phase 3 small molecule completed

    1 trial

  16. PRAX-222

    Chongqing Precision Biotech Co., Ltd

    Voltage-gated sodium channel type II alpha subunit (SCN2A) developmental and epileptic encephalopathy (DEE)

    phase 3 small molecule active

    1 trial

  17. PRAX-562

    Chongqing Precision Biotech Co., Ltd

    SCN2A Encephalopathy

    phase 3 small molecule active

    1 trial

  18. PRAX-628, PRAX-628, PRAX-628, PRAX-628

    Chongqing Precision Biotech Co., Ltd

    Focal onset seizures or primary generalized tonic-clonic seizures.

    phase 3 small molecule active

    1 trial

  19. PRAX-628, PRAX-628, Placebo for PRAX-628, PRAX-628

    Chongqing Precision Biotech Co., Ltd

    Focal Epilepsy

    phase 3 small molecule active

    1 trial

  20. PREDNISOLONE , Dupixent 300 mg solution for injection in pre-filled syringe, Placebo matching to dupilumab

    Lacuna Pharma Pty Ltd

    Bullous Pemphigoid

    phase 3 small molecule active

    1 trial

  21. PREDNISOLONE , PREDNISONE , -, Ifinatamab Deruxtecan, PARACETAMOL , -, DOCETAXEL , -, -, -

    Merck Sharp and Dohme

    Metastatic Castration-Resistant Prostate Cancer

    phase 3 small molecule active

    1 trial

  22. PREDNISOLONE , Verzenios 50 mg film-coated tablets, Placebo to match LY2835219 (Abemaciclib) Tablets, Placebo to match LY2835219 (Abemaciclib) Capsules, PREDNISONE , ABIRATERONE

    Eli Lilly Co.

    Prostate Cancer

    phase 3 small molecule active

    1 trial

  23. PREDNISOLONE, CORTISONE ACETATE, FLUDROCORTISONE, Gohibic, TRIAMCINOLONE, PREDNISONE, DEXAMETHASONE, HYDROCORTISONE, METHYLPREDNISOLONE, IFX-1 placebo is formulated as PBS (150 mM sodium chloride, 10 mM sodium phosphate, pH 7.0) with 0.05% polysorbate 80. IFX-1 placebo is diluted in sterile 0.9% sodium chloride to the required concentration and volume. This diluent is a commercial product not accompanying IFX-1 placebo., BETAMETHASONE

    InflaRx GmbH

    ulcerative pyoderma gangrenosum

    phase 3 small molecule active

    1 trial

  24. PREDNISOLONE, Placebo for Depemokimab Injection, Placebo for Prednisolone

    GlaxoSmithKline

    Hypereosinophilic Syndrome (HES)

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β€” verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources